MedTrace Logo

Using Imaging Data and Genomic Data to Predict Metastasis of Breast Cancer After Treatment

NCT03941639 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 95

Last updated 2025-02-13

No results posted yet for this study

Summary

Breast cancer is the second leading cause of death for women around the world. Notably, most breast cancer patients die from tumor metastases in the liver, lungs, bones, or brain, not the primary tumor itself. Currently, clinicians are generally successful in treating primary tumors using standard protocols that are based on tumor sub-type and staging, as well as by the presence or absence of prognostic biomarkers. However, it remains difficult to assess in advance the likelihood of metastasis or relapse in any given patient.Physicians can only rely on regular post-treatment screening to monitor any secondary onset. By the time metastasis is detected, the golden window for treatment adjustment has often already passed.

This project proposes to develop an analytical tool for predicting the likelihood of metastasis in breast cancer patients post-treatment using imaging and genomic data. We will evaluate our prediction model using prospectively-collected patient data. This new prognostic tool will enable physicians to adjust and tailor therapeutic strategies to each patient in a timely manner. Overall, the tool will personalize patient care, and improve their survival chances and quality of life.

Conditions

Sponsors & Collaborators

  • Department of Electronic and computer engineering, HKUST

    collaborator UNKNOWN

  • Department of clinical oncology, CUHK

    collaborator UNKNOWN

  • Department of Anatomical and Cellular Pathology,PWH

    collaborator UNKNOWN

  • Department of Surgery, North District Hospital

    collaborator UNKNOWN

  • Chinese University of Hong Kong

    lead OTHER

Principal Investigators

  • Weichuan Yu, Ph.D · Department of Electronic and computer engineering, HKUST

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-01
Primary Completion
2022-09-30
Completion
2022-12-31

Countries

  • Hong Kong

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03941639 on ClinicalTrials.gov